PRAX — Praxis Precision Medicines Share News
0.000.00%
Last trade - 00:00Street View: Praxis surprises Street with trial win, sees blockbuster potential
Praxis Precision Medicines extends rally after $525 mln stock sale
Praxis announces planned equity offering after stock nearly triples
U.S. STOCKS ON THE MOVE-Bitfarms, Progyny, ManpowerGroup
U.S. STOCKS ON THE MOVE-DoorDash, Praxis, Snowflake
Praxis soars as movement disorder drug meets trial goals
U.S. STOCKS ON THE MOVE-United Airlines, Fossil Group, T-Mobile
U.S. STOCKS ON THE MOVE-Taiwan Semiconductor, HP, Salesforce
Brief: Praxis Precision Medicines Announces Positive Results From Phase 3 Studies
Praxis jumps as movement disorder drug meets trial goals
Praxis drug shows promise in improving daily function for movement disorder patients (updated)
Praxis Precision Medicines' movement disorder drug shows promise in trials
Brief: Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule
Brief: Praxis Precision Medicines Terminates 2024 Sales Agreement With Jefferies - SEC Filing
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-BOK Financial, Sable Offshore, Zscaler
U.S. RESEARCH ROUNDUP-Home Depot, News, Premier
Praxis Precision Medicines Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Praxis Precision Medicines Announces Positive Results In Patients With Focal Onset Seizures From Vormatrigine